Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Conversation
The Conversation
Science
Martin Clasby, Research Assistant Professor of Medicinal Chemistry, University of Michigan

Discovering new drugs is a long and expensive process – chemical compounds that dupe screening tools make it even harder

Pan-assay interference compounds, or PAINS, often come up as false positives when researchers screen for potential drug candidates. unol/iStock via Getty Images Plus

Modern drug discovery is an expensive and complicated process. Hundreds of scientists and at least a decade are often required to produce a single medicine. One of the most critical steps in this process is the first one – identifying new chemical compounds that could be developed into new medicines.

Researchers rely heavily on bioassays to identify potential drug candidates. These tests measure a compound’s ability to act on a biological target of interest. Candidates that show up as a “hit” by interacting with a target of interest (such as fitting into a binding site on the target) move on to further study and development. Advances in technology called high-throughput screening have allowed researchers to run thousands of compounds through bioassays in a short time, significantly streamlining the process.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.